Evidence supporting the use of: Betulinic acid
For the health condition: Leukemia

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Synopsis of Evidence Supporting Betulinic Acid for Leukemia

Betulinic acid is a pentacyclic triterpenoid found in the bark of several plant species, notably birch trees (Betula spp.). Its potential anti-cancer properties, including effects on leukemia, have been explored primarily in preclinical research.

Several in vitro studies have demonstrated that betulinic acid can induce apoptosis (programmed cell death) in various leukemia cell lines, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cells. For example, a publication in Cancer Letters (2003) showed that betulinic acid triggered apoptosis in human leukemia HL-60 cells via mitochondrial pathways. Additional studies have confirmed similar pro-apoptotic effects in other leukemia models, suggesting that betulinic acid targets mitochondrial membranes, leading to cytochrome c release and caspase activation.

Despite these promising laboratory findings, there is a lack of clinical studies evaluating the safety and efficacy of betulinic acid in human leukemia patients. No large-scale animal or human trials have been completed to date. Thus, while the mechanism of action is biologically plausible and supported by cellular data, the evidence remains preliminary.

In summary, betulinic acid’s use in leukemia is supported by basic scientific research, but clinical validation is lacking. Its evidence rating is low (2/5), reflecting early-stage, mostly preclinical evidence without robust human data. Betulinic acid should not be considered a proven or standard treatment for leukemia outside of research contexts.

More about betulinic acid
More about Leukemia

Products containing betulinic acid

We currently have no products on Vitabase that contain this ingredient.